This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: Observation ROS1-Fusion-therapuTrial
status: Final
category: Laboratory, Genetics
code: Therapeutic Implication
effective: 2023-02-01
performer: Practitioner Test Dolin
derivedFrom: Observation Genetic variant assessment
component
code: Associated phenotype
value: Non-small cell lung cancer
component
code: Medication assessed
value: Taletrectinib
component
code: Associated Therapy
value: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
component
Related Artifact for Observation component: No display for RelatedArtifact (type: citation; url: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment)
code: Level of evidence
value: Tier I - Level A